Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

CBR1 and CBR3 pharmacogenetics and their influence on doxorubicin disposition in Asian breast cancer patients.

Cancer science - 1 Oct 2008

Lal Suman, Sandanaraj Edwin, Wong Zee Wan, Ang Peter C S, Wong Nan Soon, Lee Edmund J D, Chowbay Balram

Abstract excerpt

The present study aimed to identify polymorphic genes encoding carbonyl reductases (CBR1, CBR3) and investigate their influence on doxorubicin disposition in Asian breast cancer patients (n = 62). Doxorubicin (60 mg/m(2)) was administered every 3 weeks for four to six cycles and the pharmacokinet...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Alcohol Oxidoreductases
Share to Antibiotics, Antineoplastic
Share to Area Under Curve

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Breast Neoplasms

Share to Doxorubicin

Share to Half-Life

Share to Metabolic Clearance Rate

Share to Pharmacogenetics

Source

Open in PubMed Open full text

Identifiers

PMID: 19016765
DOI: 10.1111/j.1349-7006.2008.00903.x
PMCID: PMC11160041

Genes

CBR1
CBR3

Variants

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 4 Sept 2026. Prepared record publication-19016765-2026-09-04.2. Manifest publication-graph-cohort-2026-09-04.2.

Source receipt: PubMed via Helena Literature Corpus, retrieved 4 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

CBR1 and CBR3 pharmacogenetics and their influence on doxorubicin disposition in Asian breast cancer patients.PMID 19016765Read ↗

Genotype of human carbonyl reductase CBR3 correlates with doxorubicin disposition and toxicity.Semantic proximity Read ↗

Correlation of aldo-ketoreductase (AKR) 1C3 genetic variant with doxorubicin pharmacodynamics in Asian breast cancer patients.Semantic proximity Read ↗

Effects of pharmacogenetics on pharmacokinetics and toxicity of doxorubicin in Egyptian breast cancer patients.Semantic proximity Read ↗

Pharmacogenetics of ABCB5, ABCC5 and RLIP76 and doxorubicin pharmacokinetics in Asian breast cancer patients.Semantic proximity Read ↗

Pharmacogenetics of genes across the doxorubicin pathway.Semantic proximity Read ↗

Risk factors for anthracycline-associated cardiotoxicity.Semantic proximity Read ↗

Naturally occurring variants of human CBR3 alter anthracycline in vitro metabolism.Semantic proximity Read ↗

Pharmacogenetics as a Future Tool to Risk-Stratify Breast Cancer Patients According to Chemotoxicity Potential from the Doxorubicin Hydrochloride and Cyclophosphamide (AC) RegimenSemantic proximity Read ↗

Pharmacogenetics of Drug Metabolism: The Role of Gene Polymorphism in the Regulation of Doxorubicin Safety and EfficacySemantic proximity Read ↗

Pharmacogenetics of human carbonyl reductase 1 (CBR1) in livers from black and white donors.Semantic proximity Read ↗

Identification of the promoter of human carbonyl reductase 3 (CBR3) and impact of common promoter polymorphisms on hepatic CBR3 mRNA expression.Semantic proximity Read ↗

Drugs Metabolism-Related Genes Variants Impact on Anthracycline-Based Chemotherapy Induced Subclinical Cardiotoxicity in Breast Cancer PatientsSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.